Provided herein are compositions for the treatment and/or prevention of cardiovascular disease (CVD), and methods of application and use thereof. In particular, the present invention provides treatment and/or prevention of cardiovascular disease with compounds that inhibit the production of TMA in the gut, such as 3,3-dimethyl-1-butanol (DMB) or other compounds represented by Formula I or as shown in FIGS. 20-23.

Provided herein are compositions for the treatment and/or prevention of cardiovascular disease (CVD), and methods of application and use thereof. In particular, the present invention provides treatment and/or prevention of cardiovascular disease with compounds that inhibit the production of TMA in the gut, such as 3,3-dimethyl-1-butanol (DMB) or other compounds represented by Formula I or as shown in FIGS. 20-23.

Provided herein are compositions for the treatment and/or prevention of cardiovascular disease (CVD), and methods of application and use thereof. In particular, the present invention provides treatment and/or prevention of cardiovascular disease with compounds that inhibit the production of TMA in the gut, such as 3,3-dimethyl-1-butanol (DMB) or other compounds represented by Formula I or as shown in FIGS. 20-23.

The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain di-isopropyl-phosphinoyl-alkanes as described herein (DIPA-1-5, DIPA-1-6, DIPA-1-7, DIPA-1-8, and DIPA-1-9, collectively referred to herein as “DIPA compounds”) that are useful, for example, in the treatment of disorders (e.g., diseases) including: sensory discomfort (e.g., caused by irritation, itch, or pain); a skin dysesthesia; dermatitis; psoriasis; ocular discomfort; heat discomfort; heat stress; flushing and/or night sweats (vasomotor symptoms) in post-menopausal women; post-operative hypothermia; post-anaesthetic shivering; fatigue; tiredness; depression; cognitive dysfunction; and to enhance cognitive function. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, for example, in therapy.

The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain di-isopropyl-phosphinoyl-alkanes as described herein (DIPA-1-5, DIPA-1-6, DIPA-1-7, DIPA-1-8, and DIPA-1-9, collectively referred to herein as “DIPA compounds”) that are useful, for example, in the treatment of disorders (e.g., diseases) including: sensory discomfort (e.g., caused by irritation, itch, or pain); a skin dysesthesia; dermatitis; psoriasis; ocular discomfort; heat discomfort; heat stress; flushing and/or night sweats (vasomotor symptoms) in post-menopausal women; post-operative hypothermia; post-anaesthetic shivering; fatigue; tiredness; depression; cognitive dysfunction; and to enhance cognitive function. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, for example, in therapy.

Provided is an inactive compound that is activated by reaction with ozone into an active compound having a carbonyl oxygen. Also provided is a method of activating the above inactive compounds. Further provided is a method of treating a disease or condition in a subject using the above compound at a site that is not exposed to atmospheric ozone. Additionally provided is a method of determining internal ozonolysis in a subject using the above compound. Also provided is a molecule less than 1000 mw, having a double bond that is reactive with ozone, and forms a nontoxic compound after reacting with ozone. Further provided is a method of degrading ozone.

Provided is an inactive compound that is activated by reaction with ozone into an active compound having a carbonyl oxygen. Also provided is a method of activating the above inactive compounds. Further provided is a method of treating a disease or condition in a subject using the above compound at a site that is not exposed to atmospheric ozone. Additionally provided is a method of determining internal ozonolysis in a subject using the above compound. Also provided is a molecule less than 1000 mw, having a double bond that is reactive with ozone, and forms a nontoxic compound after reacting with ozone. Further provided is a method of degrading ozone.

In one aspect, the disclosure relates to substituted spectinomycin analogs, including substituted aminomethyl spectinomycin analogs and substituted spectinamide analogs, with increased tolerability and safety, including improved tolerability to parenteral administration. The present disclosure further pertains to methods of making disclosed compounds, pharmaceutical compositions comprising the disclosed compounds, and methods of treating microbial infections using the disclosed compounds, including methods of treating antibiotic resistant infections and tuberculosis. This abstract is intended as a scanning tool for pur-poses of searching in the particular art and is not intended to be limiting of the present disclosure.

In one aspect, the disclosure relates to substituted spectinomycin analogs, including substituted aminomethyl spectinomycin analogs and substituted spectinamide analogs, with increased tolerability and safety, including improved tolerability to parenteral administration. The present disclosure further pertains to methods of making disclosed compounds, pharmaceutical compositions comprising the disclosed compounds, and methods of treating microbial infections using the disclosed compounds, including methods of treating antibiotic resistant infections and tuberculosis. This abstract is intended as a scanning tool for pur-poses of searching in the particular art and is not intended to be limiting of the present disclosure.

The present invention pertains to methods of using certain 1-di-isopropyl-phosphinoylalkanes as described herein (DIPA-1-7, DIPA-1-8, and DIPA-1-9, collectively referred to herein as “DIPA compounds”) for the treatment of ocular discomfort that is caused by eye strain; eye surgery; an airborne irritant or pollutant that interacts with the eye surface; heat discomfort; extended wear of contact lenses; excessive exposure to the sun; asthenopia; conjunctivitis; or a dry eye syndrome. The present invention also pertains to pharmaceutical compositions comprising such compounds, and media contain those pharmaceutical compositions.